HCW Biologics Inc.

HCWB

US40423R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-01 pm EST			5-day change	1st Jan Change
1.140 ^USD	+5.56%		-1.72%	-40.46%

Nov. 14	HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Nov. 14	Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102	MT

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about HCW Biologics Inc.

HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102	Nov. 14	MT
HCW Biologics Inc. Announces Results from Preliminary Human Data Readout from an Ongoing Phase 1 Clinical Trial Sponsored by the University of Minnesota	Nov. 08	CI
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Aug. 11	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $622,807	Aug. 11	MT
Hcw Biologics Inc. Announces Appointment of Rick S. Greene as Class II Director	Jun. 14	CI
HCW Biologics Says It Received Patent for Methods to Treat Diseases Caused by Chronic Inflammation	Jun. 14	MT
EF Hutton Assumes HCW Biologics at Buy With $9 Price Target	Jun. 01	MT
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	May. 09	CI
Hcw Biologics Inc. Secures $26.25 Million Non-Dilutive Financing with Asset-Backed Development Loan	Apr. 27	CI
HCW Biologics Inc. announced that it expects to receive $26.25 million in funding	Apr. 19	CI
HCW Biologics Inc. Enters Cooperative Research and Development Agreement with National Cancer Institute	Dec. 08	CI
JonesTrading Starts HCW Biologics at Buy With $8 Price Target	Nov. 08	MT
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	Nov. 07	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $361.8M	Nov. 07	MT
HCW Biologics Files $100 Million Mixed Shelf	2022	MT
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	2022	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $166,800	2022	MT
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q1 Revenue $3.12M	2022	MT
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	2022	CI
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	2022	CI
Maxim Initiates HCW Biologics at Buy With $4 Price Target	2022	MT
HCW Biologics Up After University Cleared to Proceed With Solid Tumors Trial	2022	DJ
HCW Biologics Says it Gets FDA Clearance for Phase 1 Trial of Cancer Drug Candidate; Shares Rise Pre-Bell	2022	MT
Certain Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 15-JAN-2022.	2022	CI

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company uses its Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the senescence-associated phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9218 is being evaluated in two clinical trials. HCW9302 is designed to activate and expand regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors.

Sector

Biotechnology & Medical Research

Calendar

2024-03-25 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.140USD

Average target price

4.000USD

Spread / Average Target

+250.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HCW BIOLOGICS INC.	-40.46%	41 M $
VERTEX PHARMACEUTICALS INCORPORATED	+21.60%	90 488 M $
REGENERON PHARMACEUTICALS, INC.	+12.94%	86 658 M $
WUXI APPTEC CO., LTD.	+2.47%	34 551 M $
ARGENX SE	+19.81%	26 777 M $
BIONTECH SE	-33.83%	23 629 M $
GENMAB A/S	-26.62%	20 547 M $
BEIGENE, LTD.	-14.75%	19 529 M $
NEUROCRINE BIOSCIENCES, INC.	-1.94%	11 507 M $
LEGEND BIOTECH CORPORATION	+20.17%	10 906 M $